![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $45.5 million, which will...
Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE...
CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (βAnchianoβ) today announced an update with respect to its intention to voluntarily...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions